Target intelligence / Profile preview

Gamma-aminobutyric acid transporter 3 (GAT-3)

Target
GAT-3
Molecular classification
Transporter, Solute carrier protein (SLC family 6 member 11), Neurotransmitter transporter
01

Overview

Gamma-aminobutyric acid transporter 3 (GAT-3, SLC6A11) is a sodium- and chloride-dependent membrane transporter primarily expressed in astrocytic processes throughout the brain, notably in the cerebral cortex and globus pallidus[2][1][7]. It mediates high-affinity uptake of GABA—the major inhibitory neurotransmitter in the central nervous system—removing GABA from the synaptic cleft and thus regulating both the magnitude and duration of inhibitory neurotransmission[1][2][4][7]. By rapidly clearing GABA, GAT-3 helps maintain synaptic precision and prevent spillover-mediated tonic inhibition. Differential regional expression and selective function in glia distinguish GAT-3 from other GABA transporters. The transporter has been implicated in pathology, including alcohol dependence, and is an emerging target for neurological and addiction-related drug development[3][5].

Other names
GABA transporter type 3SLC6A11Sodium- and chloride-dependent GABA transporter 3
02

Mechanism of action

Reuptake blockade: Inhibitors increase extracellular GABA by blocking GAT-3-mediated reuptake into astrocytes[1][5] Enhanced GABAergic tone may decrease excitability in certain brain regions

03

Biological functions

Regulates extracellular GABA concentrationTerminates GABAergic synaptic transmission via reuptake of GABA into glial cells (primarily astrocytes)Modulates neuronal excitability and synaptic signaling
04

Disease associations

Neurological diseaseAddiction (notably alcoholism)Potential involvement in epilepsy and other GABA-related disorders
05

Safety considerations

Over-inhibition can lead to excessive extracellular GABA, potentially impairing normal synaptic transmissionTargeting astrocytic transporters may have off-target neural or metabolic effectsSelectivity over other GABA transporters remains a pharmacological challenge[6]
06

Interacting drugs

Subtype-selective GAT-3 inhibitors (recent development)

1 more in the full profile.

07

Biomarkers

Decreased GAT-3 expression in post-mortem alcoholic brains[3]Changes in GAT-3 levels may serve as a biomarker for GABAergic dysfunction in specific disease contexts

Beyond the preview

Go deeper on Gamma-aminobutyric acid transporter 3 (GAT-3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-aminobutyric acid transporter 3 (GAT-3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call